CN106796221B - 川崎氏症的诊断与治疗 - Google Patents

川崎氏症的诊断与治疗 Download PDF

Info

Publication number
CN106796221B
CN106796221B CN201580040004.5A CN201580040004A CN106796221B CN 106796221 B CN106796221 B CN 106796221B CN 201580040004 A CN201580040004 A CN 201580040004A CN 106796221 B CN106796221 B CN 106796221B
Authority
CN
China
Prior art keywords
amount
individual
biomarker
disease
kawasaki
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580040004.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN106796221A (zh
Inventor
陈垣崇
邬哲源
柯泰名
郭和昌
张正成
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academia Sinica
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of CN106796221A publication Critical patent/CN106796221A/zh
Application granted granted Critical
Publication of CN106796221B publication Critical patent/CN106796221B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5418—IL-7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/328—Vasculitis, i.e. inflammation of blood vessels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201580040004.5A 2014-07-24 2015-07-23 川崎氏症的诊断与治疗 Active CN106796221B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462028633P 2014-07-24 2014-07-24
US62/028,633 2014-07-24
PCT/US2015/041687 WO2016014761A1 (en) 2014-07-24 2015-07-23 Diagnosis and treatment of kawasaki disease

Publications (2)

Publication Number Publication Date
CN106796221A CN106796221A (zh) 2017-05-31
CN106796221B true CN106796221B (zh) 2019-12-17

Family

ID=55163743

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580040004.5A Active CN106796221B (zh) 2014-07-24 2015-07-23 川崎氏症的诊断与治疗

Country Status (7)

Country Link
US (1) US10983133B2 (enExample)
JP (1) JP6779200B2 (enExample)
KR (1) KR102453756B1 (enExample)
CN (1) CN106796221B (enExample)
CA (1) CA2955214C (enExample)
TW (2) TWI655433B (enExample)
WO (1) WO2016014761A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI683905B (zh) * 2017-11-21 2020-02-01 長庚醫療財團法人高雄長庚紀念醫院 用於檢測川崎氏病的方法及套組以及用於治療川崎氏病的方法
KR102056405B1 (ko) * 2018-04-05 2019-12-16 (주)메디젠휴먼케어 Ebf2 유전자 다형성을 이용한 가와사키병 발병 예측 방법
AU2019317990B2 (en) * 2018-08-04 2025-04-24 Imperial College Innovations Limited Method of identifying a subject having Kawasaki disease
CN113834939A (zh) * 2021-09-18 2021-12-24 胜亚生物科技(厦门)有限公司 一种用于检测川崎病及疗效评估的试剂、试剂盒及应用
WO2024037387A1 (en) * 2022-08-19 2024-02-22 Tianjin Yunjian Medical Technology Co., Ltd. Blood biomarkers and methods for diagnosis of acute kawasaki disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3888224T2 (de) 1987-04-24 1994-07-21 Teijin Ltd Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung.
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
WO2010025393A2 (en) 2008-08-28 2010-03-04 The Regents Of The University Of California Protein biomarkers and methods for diagnosing kawasaki disease
WO2012112315A2 (en) * 2011-02-20 2012-08-23 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of kawasaki disease
US9869673B2 (en) 2011-04-15 2018-01-16 The Children's Medical Center Corporation Diagnostic markers and therapeutic targets of kawasaki disease
LT2852615T (lt) * 2012-05-22 2019-02-11 Bristol-Myers Squibb Company Il-17a/f il-23 bispecifiniai antikūnai ir jų panaudojimai
WO2014043397A1 (en) 2012-09-12 2014-03-20 Indiana University Research & Technology Corporation Material and methods for diagnosing and treating kawasaki disease and kls

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
chemokines in Kawasaki disease Measurement of CCL2，CCL22 and CXCL10;Yasufumi shikishima，et al;《ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY》;20031231;第21卷;摘要，140页第1栏第4段、第2栏第4段、第3栏第4段，图3，第142页第1栏第2段 *

Also Published As

Publication number Publication date
WO2016014761A1 (en) 2016-01-28
TW201617613A (zh) 2016-05-16
KR20170039139A (ko) 2017-04-10
JP2017524933A (ja) 2017-08-31
KR102453756B1 (ko) 2022-10-12
TW201706600A (zh) 2017-02-16
US10983133B2 (en) 2021-04-20
JP6779200B2 (ja) 2020-11-04
CN106796221A (zh) 2017-05-31
TWI598586B (zh) 2017-09-11
US20170153250A1 (en) 2017-06-01
CA2955214C (en) 2023-03-21
TWI655433B (zh) 2019-04-01
CA2955214A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
US10338083B2 (en) Pathway specific markers for diagnosing irritable bowel syndrome
CN106796221B (zh) 川崎氏症的诊断与治疗
Song et al. Single molecule measurements of tumor necrosis factor α and interleukin-6 in the plasma of patients with Crohn's disease
Koshiol et al. Circulating inflammatory proteins and gallbladder cancer: Potential for risk stratification to improve prioritization for cholecystectomy in high-risk regions
Xu et al. Evaluation and validation of the prognostic value of anti-MDA5 IgG subclasses in dermatomyositis-associated interstitial lung disease
CN105849566A (zh) 肾脏疾病生物标志物
WO2013009183A1 (en) Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness
JP6153239B2 (ja) 川崎病の検査方法およびキット
US20180011110A1 (en) Methods and Compositions in Diagnosis of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis
US8501494B1 (en) Method and device for detecting prior drug use, taking inflammation into account to increase test's specificity and reduce false positives
WO2017168014A1 (de) Markersequenzen für rheumatoide arthritis
Zülfikaroğlu et al. Role of serum levels of tumour necrosis factor-like weak inducer of apoptosis (TWEAK) in predicting severity of acute appendicitis
Hiura et al. Diagnostic Performance of the Multi-Biomarker Disease Activity (MBDA) Score for Rheumatoid Arthritis in Patients with New-Onset Joint Symptoms: An Age-Stratified Retrospective Study
Liu et al. B-112 HLA-DQ Genotypes as Predictors of Serological Positivity for Celiac Disease in Pediatric Patients
WO2025217554A1 (en) Systems and methods for detecting specific subspecies of autoantibodies and methods of use thereof
Jiang et al. B-103 KFLC-index distinguishes multiple sclerosis from anti-myelin oligodendrocyte glycoprotein and aquaporin 4 diseases in a Chinese cohort
龍城真衣子 Serological Cytokine Signature in Paediatric Patients with Inflammatory Bowel Disease Impacts Diagnosis
TWI564560B (zh) 檢測自體免疫風濕性疾病之方法
WO2021210651A1 (ja) 重症薬疹のタンパク質診断バイオマーカー
JP2011252784A (ja) 再発性多発軟骨炎の検査方法およびそれに用いられる検査キット
TW202014706A (zh) 一種檢測糖尿病腎病變的方法
US20140186933A1 (en) Method and device for detecting prior drug use, taking inflammation into account to increase test's specificity and reduce false positives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20200422

Address after: Taiwan China

Patentee after: ACADEMIA SINICA

Address before: Taiwan Taipei

Co-patentee before: ACADEMIA SINICA

Patentee before: Chen Yuanchong